Core Framework & Diagram Major Misconceptions in Immunology History
July 24, 20261 Min Read Major Breakthroughs in Immunology History
July 24, 2026Things we were certain were true — that later turned out to be wrong
—— Understanding these misconceptions is how we avoid repeating them.
I. 'Innate immunity has no memory': a fifty-year misconception
This misconception existed in immunology textbooks for at least fifty years before 2009 began to shake it. Its origin is clear: the hallmark features of adaptive immunity are 'specificity' and 'memory' — T and B cells after contacting antigen undergo clonal expansion, producing large numbers of cells recognizing the same antigen, with some persisting as memory cells after infection resolves, producing faster, stronger responses on re-encounter. This process depends on highly diversified antigen receptors (TCR and BCR) and antigen-driven selection. Innate immunity (NK cells, macrophages, neutrophils, etc.) lacks this diversified antigen-specific receptors, relying on 'pattern recognition receptors' (PRR) recognizing pathogen conserved molecular features (PAMP). Since PRR are germline-encoded and don't undergo antigen-driven clonal selection, mainstream theory at the time believed innate immune cells wouldn't 'remember' this encounter after each infection, and next responses' strength and speed wouldn't change because of it.
The 2009 NK cell memory discovery and Mihai Netea's team's 2011 'Trained Immunity' concept completely overturned this assumption. Trained immunity describes an epigenetic mechanism — monocytes and macrophages after experiencing specific microbial stimulation (like BCG, β-glucan) have changes in chromatin accessibility and histone modification patterns, making these cells respond faster and stronger against future non-specific threats, with this change lasting months. This 'memory' doesn't depend on antigen-specific receptors but on epigenetic reprogramming — a memory mechanism completely different from adaptive immunity, but equally real. This misconception's correction has profound implications for vaccine science. BCG vaccine's non-specific protection effects (reducing overall infectious disease mortality beyond tuberculosis) precisely embody trained immunity. Understanding this mechanism provides a new framework for designing 'broad-spectrum immune enhancing vaccines.'
2. 'Stronger immunity is better': a dangerous oversimplification
This misconception still exists in large amounts of health product marketing language today, but in immunology's professional sphere, it was recognized long ago as a dangerous oversimplification. The misconception's source is intuitive logic: immune system's function is body protection; stronger immune system = better protection. This logic is correct in some contexts — HIV infection causing severe CD4+ T cell reduction is essentially greatly reduced immunity, causing opportunistic infections; during post-bone marrow transplant immune reconstitution, patients are highly infection-prone due to low immunity. In these contexts, 'stronger immunity' really is better. But the immune system is not a unidirectional quantity for 'the stronger the better' — it's a highly precisely regulated balancing system. When this balance breaks — immune responses continue strongly and can't be effectively suppressed — the result isn't better protection but autoimmune disease, chronic inflammation, or acute cytokine storms.
SLE patients' immune systems, in a sense, can be described as 'too active' — producing large amounts of autoantibodies, continuously attacking self-tissue. RA patients' joint destruction is the result of Th17 cells and inflammatory cytokines' over-activation — not immunity too weak, but certain direction of immunity 'too strong.' Allergic diseases (asthma, hay fever, food allergy) are immune system over-responses to harmless antigens. This misconception caused two types of practical harm. First, patient level: large amounts of health products claiming to 'boost immunity' are extensively purchased by consumers without any evidence, while in practice for healthy people with normal immune balance, so-called 'immune enhancement' is at best ineffective, at worst may worsen certain people's inflammation risks. Second, clinical level: early immune activation therapies in oncology (like high-dose IL-2) caused serious toxicity (capillary leak syndrome) due to non-specific over-activation of the immune system — a direct clinical failure of 'stronger is better' logic.
3. 'Nervous and immune systems are independent': the wall between two giants
From the nineteenth century to mid-twentieth century, neuroscience and immunology developed as two independent disciplines with almost no overlap. This separation had historical reasons: the two disciplines differed enormously in research objects, methods, and academic traditions; the brain was considered an 'immune-privileged' organ (protected by the blood-brain barrier, immune cells difficult to enter); and the nervous system was considered wholly unrelated to immune responses. This assumption began being systematically questioned in the 1980s. Neuroendocrine immunology gradually formed as a cross-disciplinary field. Key discoveries emerged one after another: immune cells carry neurotransmitter receptors — T cells, B cells, and NK cells all express adrenergic receptors, acetylcholine receptors, dopamine receptors, meaning signaling molecules secreted by the nervous system can directly regulate immune cell function; cortisol secreted by the hypothalamic-pituitary-adrenal (HPA) axis is one of the immune system's most important endogenous inhibitors; the vagus nerve (parasympathetic nervous) through the 'cholinergic anti-inflammatory pathway' can directly suppress inflammation — stimulating vagus nerve can reduce inflammation in sepsis animal models.
In the brain itself, the concept of 'immune privilege' is also being continuously revised. Although the blood-brain barrier does limit peripheral immune cell entry, the brain has its own resident immune cells — microglia, which participate in synaptic pruning during development, activate inflammatory responses during infection and injury, and play key pathological roles in neurodegenerative diseases (like Alzheimer's). Additionally, brain meningeal lymphatics discovered in 2015 completely changed the understanding of the brain as an 'immunological island' — the brain maintains continuous material exchange with the peripheral immune system through the meningeal lymphatic system. This misconception's correction drove formation of psychoneuroimmunology (PNI) — studying how psychological states affect immune function through the neural-endocrine-immune axis. Large amounts of research confirmed that chronic stress, depression, and loneliness correlate with declined immune function, while exercise, meditation, and social support correlate with improved immune function.
4. 'Thymus is a useless organ': an almost discarded key
The thymus is one of the human body's most counterintuitive organs. It's relatively large at birth (about twelve to fifteen grams), peaks at puberty (about thirty-five to forty grams), then progressively atrophies with age (replaced by fat). This 'use then discard' pattern confused nineteenth-century anatomists and physicians — an organ that disappears with age, what use does it have? Before antibiotics existed, pediatricians once attributed 'sudden infant death syndrome' to the thymus 'too large' pressing on the trachea, and developed a therapy of using X-rays to irradiate the thymus to make it atrophy — a therapy used for decades, later found to increase thyroid cancer risk in these children in adulthood. This is direct harm caused by misunderstanding of the thymus in medical history. In the 1960s, Jacques Miller cut out the thymus from newborn mice and observed shocking results: these mice could almost completely not produce cellular immune responses, were prone to dying from infection, and couldn't reject allogeneic skin grafts. Further research found the thymus is the necessary site for T cell development and maturation — precursor T cells from hematopoietic stem cells experience positive selection (recognizing MHC) and negative selection (deleting self-reactive T cells) in the thymus, then entering peripheral circulation as mature cells. Thymus atrophy after adulthood is not because it becomes useless, but because the T cell repertoire has been basically established in early development. Thymic atrophy is one of the important causes of elderly immune function decline (immunosenescence).
5. 'Immune tolerance is a passive blacklist system': underestimating Treg
Burnet's clonal deletion theory (1959 Nobel) proposed: during T and B cell development, cell clones capable of recognizing self-antigens are deleted (apoptosis), thus establishing tolerance to self-components. This theory is correct for establishing central tolerance, but implies an overly simple picture: immune tolerance = clearing self-reactive cells, a one-time, central-level clearance process. Even though clonal deletion isn't complete — even after strict negative selection, the peripheral circulation still contains some T cells capable of recognizing self-antigens. In autoimmune disease patients, these 'escaped' self-reactive T cells activated and caused disease. What mechanism in healthy people prevented these cells from launching attacks? The answer gradually became clear around 2003: regulatory T cells (Treg), especially natural Treg expressing transcription factor Foxp3, are the active executors of peripheral immune tolerance. Treg are preferentially selected and produced in the thymus, specializing in suppressing other T cells' over-activation in peripheral tissue. They're not just a clearance list but continuous, active 'immune police' — through secreting IL-10, TGF-β and other inhibitory cytokines, and direct cell contact, continuously suppressing self-reactive T cell activity. Foxp3 gene discovery (2003) and Treg's functional characterization completely changed the conceptual framework of immune tolerance: it's not a passive state after 'blacklist clearance,' but a dynamic process requiring continuous, active maintenance. Treg also simultaneously opened an important tumor immunology research direction: the tumor microenvironment is enriched with large numbers of Treg actively suppressing anti-tumor immune responses, making Treg depletion in tumor microenvironment an important strategy for improving immunotherapy effects.
6. Learning from the history of misconceptions
Reviewing these misconceptions, there's a shared lesson: every corrected misconception, in its era of prevalence, had reasonable evidence support and was the best judgment possible under the best available tools and frameworks. This means: the immunological knowledge we have today, though more abundant and precise than any previous era, is not therefore immune to future tools and frameworks' modification. For ordinary people, understanding these misconceptions has most practical value in: maintaining skepticism about products claiming to 'boost immunity'; understanding the immune system needs balance not unidirectional enhancement; recognizing that psychological states (stress, emotions) have physiologically grounded impact on immune function, not superstition; and maintaining appropriate cognitive humility about 'latest immunology research shows...' type headlines — new discoveries before being fully validated may conflict with existing frameworks, requiring more evidence to confirm. For the scientific community, immunology's misconception history provides an important methodological hint: when a conclusion shows divergent results across different laboratories, different species, and different experimental conditions, rather than insisting on using existing frameworks to explain differences, consider whether the existing framework has fundamental blind spots. Those results called 'anomalous data' are sometimes precisely the signals pointing toward the next major discovery.
Frequently Asked Questions